Foventa Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Series A
  • (Upcoming)

  • Investors
  • 11

Foventa Therapeutics General Information

Description

Developer of a biopharmaceutical drug designed to improve the treatment of patients with retinal vascular diseases and to improve the lives of those suffering from vision loss. The company offers program molecules for wet age-related macular degeneration, which act via a novel mechanism of action to inhibit pathological blood vessels and reduce the formation of pathological vascular endothelial growth factor without inhibiting beneficial, non-pathological vascular endothelial growth factor (VEGF), enabling the healthcare industry to focus on developing therapies for wet age-related macular degeneration.

Contact Information

Website
www.foventa.com
Formerly Known As
Exonate
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • WTL Moorfield Road, Duxford
  • Cambridgeshire
  • Cambridge CB22 4PS
  • England, United Kingdom
+44 01223
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • WTL Moorfield Road, Duxford
  • Cambridgeshire
  • Cambridge CB22 4PS
  • England, United Kingdom
+44 01223

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Foventa Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series A) Upcoming Clinical Trials - Phase 2
8. Secondary Transaction - Private 01-Jul-2026 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series A) 03-Jan-2019 Completed Clinical Trials - Phase 2
6. Later Stage VC 12-Sep-2018 Completed Clinical Trials - Phase 1
5. Grant 06-Feb-2017 Completed Clinical Trials - Phase 1
4. Early Stage VC 01-Dec-2016 Completed Clinical Trials - Phase 1
3. Early Stage VC 05-Oct-2015 Completed Clinical Trials - Phase 1
2. Seed Round 01-Mar-2014 $651K $651K Completed Clinical Trials - Phase 1
1. University Spin-Out 01-Jan-2013 Completed Startup
To view Foventa Therapeutics’s complete valuation and funding history, request access »

Foventa Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 14,141 $0.012877 $72.11 $72.11 1x $72.11 17.79%
Ordinary 7,860 $0.012877 $64.39 $64.39 1x $64.39 9.89%
To view Foventa Therapeutics’s complete cap table history, request access »

Foventa Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biopharmaceutical drug designed to improve the treatment of patients with retinal vascular diseases and t
Drug Discovery
Cambridge, United Kingdom
17 As of 2026

Charlottesville, VA
 

San Juan Capistrano, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Foventa Therapeutics Competitors (28)

One of Foventa Therapeutics’s 28 competitors is TearSolutions, a Venture Capital-Backed company based in Charlottesville, VA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TearSolutions Venture Capital-Backed Charlottesville, VA
Allegro Ophthalmics Venture Capital-Backed San Juan Capistrano, CA
EyePoint Corporation Watertown, MA
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA
Kala Bio Formerly VC-backed Arlington, MA
You’re viewing 5 of 28 competitors. Get the full list »

Foventa Therapeutics Patents

Foventa Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021309894-A1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Active 14-Jul-2020
AU-2021309894-B2 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Active 14-Jul-2020
CA-3183466-A1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Pending 14-Jul-2020
EP-4182311-A1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Active 14-Jul-2020
EP-4182311-B1 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases Active 14-Jul-2020 C07D405/14
To view Foventa Therapeutics’s complete patent history, request access »

Foventa Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Foventa Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
EMV Capital Venture Capital Minority
Stoic Venture Capital Venture Capital Minority
University of Bristol Endowment Limited Partner Minority
R42 Group Venture Capital Minority
Martlet Capital Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Foventa Therapeutics FAQs

  • When was Foventa Therapeutics founded?

    Foventa Therapeutics was founded in 2013.

  • Where is Foventa Therapeutics headquartered?

    Foventa Therapeutics is headquartered in Cambridge, United Kingdom.

  • What is the size of Foventa Therapeutics?

    Foventa Therapeutics has 17 total employees.

  • What industry is Foventa Therapeutics in?

    Foventa Therapeutics’s primary industry is Drug Discovery.

  • Is Foventa Therapeutics a private or public company?

    Foventa Therapeutics is a Private company.

  • What is Foventa Therapeutics’s current revenue?

    The current revenue for Foventa Therapeutics is .

  • How much funding has Foventa Therapeutics raised over time?

    Foventa Therapeutics has raised $7.74M.

  • Who are Foventa Therapeutics’s investors?

    EMV Capital, Stoic Venture Capital, University of Bristol Endowment, R42 Group, and Martlet Capital are 5 of 11 investors who have invested in Foventa Therapeutics.

  • Who are Foventa Therapeutics’s competitors?

    TearSolutions, Allegro Ophthalmics, EyePoint, Apellis Pharmaceuticals, and Kala Bio are some of the 28 competitors of Foventa Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process